MIT Technology Review September 27, 2021
Lindsay Muscato

Booster shots for some Americans were just approved—but core problems around fairness still linger, in the US and around the globe.

The US booster program is about to get underway, after the CDC backed additional shots for a large swath of the American public.

The agency now recommends that people aged 65 years and older, adults in long-term care, and those over 50 with underlying medical conditions get a third Pfizer-BioNTech shot. (Those whose first shot was Johnson & Johnson or Moderna will have to wait a little longer.) Frontline workers or those with a higher risk of infection will also get the chance to get a booster, categories added when the CDC’s director, Rochelle Walensky, overruled her committee.

But the decision...

Today's Sponsors

ZeOmega
Holon
Transcarent

Today's Sponsors

Crossover Health
Qure4u

Today's Sponsor

Institute for Healthcare Improvement

 
Topics: Biotechnology, Govt Agencies, Healthcare System, Interview / Q&A, Patient / Consumer, Pharma / Biotech, Provider, Public Health / COVID, Trends
Hospitals sustained huge financial losses from lost revenues during COVID-19 pandemic
How BioNTech went from a little-known biotech company to creating the Covid vaccine
Pandemic Plus Ransomware Is 'Perfect Storm' for Healthcare
How Employee-Focused Tech Can Help Hospitals Endure the Latest COVID Surge
mRNA Technology: First COVID-19, Now Cancer